Jpmorgan Chase & CO Entrada Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,706 shares of TRDA stock, worth $91,030. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,706
Previous 35,470
58.54%
Holding current value
$91,030
Previous $613,000
78.47%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding TRDA
# of Institutions
107Shares Held
28.8MCall Options Held
15.7KPut Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$30.1 Million0.33% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$27.1 Million67.92% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.31MShares$26.7 Million19.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.57MShares$15.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$10.5 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $194M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...